See-thru value: Why HTAs must show true drug benefit
This article was originally published in SRA
Executive Summary
News that the National Insitute for Health and Clinical Excellence in the UK is to be responsible for conducting the "full value assessment" in the country’s future value-based pricing or VBP system has again raised questions about the nature of "value" where medicines are concerned1,2.